Multiple Myeloma Committee Meeting Agenda
Saturday, November 4
8:30am-12:30pm CT

Location
Loews Chicago O’Hare
Cassat A and B

Dial-in Information
Dial-in #: 800-501-8979
Access code: 0739814

Chair: Paul Richardson, MD
Vice-Chair: Phil McCarthy, MD

I. Welcome and Introductions

II. Update from the Committee Chairs Meeting

III. Alliance and Related Studies – Completed and Ongoing

a. CALGB 100104 and derived studies in ND MM/SCT
   Sarah Holstein, MD, PhD; University of Nebraska Medical Center
   Phil McCarthy, MD; Roswell Park Cancer Institute

b. CALGB 100001: Seq chemo, STI571 & transplant in Ph+ ALL
   Sarah Holstein, MD, PhD; University of Nebraska Medical Center

c. IFM/DFCI 2009 Study in ND MM (BMT CTN 1304; the Determination trial)
   Paul Richardson, MD; Dana-Farber Cancer Institute

d. A061202: Pom/Dex +/- MLN9708 in RR MM
   Peter Voorhees, MD; Levine Cancer Institute

e. A061402: Plasmacytoma
   Anuj Mahindra, MD; Scripps Cancer Center

f. AFT-29: RVd + Dara in SCT-eligible ND MM patients (the Griffin trial)
   Peter Voorhees, MD; Levine Cancer Institute
   Jacob Laubach, MD; Dana-Farber Cancer Institute
   Paul Richardson, MD; Dana-Farber Cancer Institute

IV. Endorsed Studies

a. ECOG – E1A11: RVd vs KRd in ND MM
   Edward Faber, MD; Oncology Hematology Care Inc.

b. ECOG – E3A06: Smoldering myeloma study (lenalidomide vs placebo)
   Anuj Mahindra, MD; Scripps Cancer Center
c. SWOG – S1211: RVD +/- Elo vs KRd +/- Elo for high risk ND MM
   *Peter Voorhees, MD; Levine Cancer Institute*

d. SWOG – S1304: Carfilzomib in RR MM (completed; results pending)
   *Peter Voorhees, MD; Levine Cancer Institute*

e. BMT CTN 1302: RIC allo followed by ixazomib maintenance in newly diagnosed MM
   *Cristina Gasparetto, MD; Duke Cancer Institute*

V. Alliance Studies – Pending Activation/In Development

a. AFT-15: Ibrutinib + Rd in relapsed/refractory MM
   *Yvonne Efebera, MD; Ohio State University Medical Center*
   *Jacob Laubach, MD; Dana-Farber Cancer Institute*

b. AFT-35: PVd Dara in relapsed/refractory MM
   *Hani Hassoun, MD; Memorial Sloan-Kettering Cancer Center*
   *Paul Richardson, MD; Dana-Farber Cancer Institute*

c. AFT-40: Rev +/- multiple agents as maintenance post-ASCT
   *Sarah Holstein, MD, PhD; University of Nebraska Medical Center*
   *Phil McCarthy, MD; Roswell Park Cancer Institute*

d. AFT-41: RID +/- Dara in non-SCT eligible newly diagnosed MM patients
   *Jacob Laubach, MD; Dana-Farber Cancer Institute*
   *Betsy O'Donnell, MD; Massachusetts General Hospital*
   *Paul Richardson, MD; Dana-Farber Cancer Institute*
   *Noopur Raje, MD; Massachusetts General Hospital*

VI. New Concepts/Initiatives: Updates and New Proposals

a. Therapeutic Subcommittee in MM Older Adults
   *Tanya Wildes, MD; Washington University School of Medicine*
   *Sascha Tuchman, MD; University of North Carolina*
   *Ashley Rosko, MD; Ohio State University Medical Center*
   *Betsy O'Donnell, MD; Massachusetts General Hospital*

b. Optimal duration of lenalidomide maintenance in MRD negative patients post ASCT
   *Peter Voorhees, MD; Levine Cancer Institute*

c. Twice a week ixazomib + pom for relapsed/refractory MM
   *Paul Richardson, MD; Dana-Farber Cancer Institute*

d. New Ideas and Concepts
   *All Members of the Committee*